Related Experiment Video
Updated: May 12, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Reevaluating the accelerated approval process for oncology drugs
Wyndham H Wilson1, David P Schenkein, Cheryl L Jernigan
1Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, Maryland, USA.
Summary
To optimize the accelerated approval pathway, this study reevaluates "unmet medical need" and "available therapy" definitions in oncology. It proposes qualifying new endpoints and a structured process for developers seeking expedited drug approval.
Area of Science:
- Oncology drug development and regulatory pathways.
- Clinical trial design and endpoint qualification.
Background:
- The accelerated approval pathway requires therapies for serious diseases with unmet medical need.
- Defining unmet medical need includes novel therapies or those potentially superior to existing options.
- Challenges include numerous therapies, lack of validated surrogate endpoints, and unclear qualification criteria.
Purpose of the Study:
- To propose optimizations for the accelerated approval pathway in oncology.
- To reevaluate the definitions of "unmet medical need" and "available therapy".
- To discuss methods for qualifying new surrogate endpoints and suggest a structured application process.
Main Methods:
- Conceptual analysis and review of current regulatory standards for accelerated approval.
- Examination of the impact of increasing therapeutic options on unmet medical need criteria.
- Proposal of revised definitions and a structured framework for pathway utilization.
Main Results:
- Current criteria for accelerated approval may be misapplied due to evolving treatment landscapes.
- Pursuit of accelerated approval in heavily pretreated populations is increasing to meet perceived unmet needs.
- A need exists for clearer definitions and a more structured approach to endpoint qualification and pathway application.
Conclusions:
- Revising definitions of "unmet medical need" and "available therapy" is crucial for optimizing the accelerated approval pathway.
- Establishing clear criteria for qualifying surrogate endpoints will enhance predictability for drug developers.
- A structured process for pursuing accelerated approval can improve efficiency and regulatory clarity in oncology.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...